<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        102-368-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACILOC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        120.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AcilocTM contains the active substance omeprazole. It belongs to a group of medicines called<br />&lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach<br />produces.<br />AcilocTM is used to treat the following conditions:<br />In adults:<br />&bull; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes<br />into the gullet (the tube which connects your throat to your stomach) causing pain,<br />inflammation and heartburn.<br />&bull; Ulcers in the upper part of the intestine (duodenal ulcer) or stomach (gastric ulcer).<br />&bull; Ulcers which are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If you have this<br />condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer<br />to heal.<br />&bull; Ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).<br />AcilocTM can also be used to stop ulcers from forming if you are taking NSAIDs.<br />&bull; Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison<br />syndrome).<br />In children:<br />Children over 1 year of age and &ge; 10 kg<br />&bull; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes<br />into the gullet (the tube which connects your throat to your stomach) causing pain,<br />inflammation and heartburn.<br />In children, the symptoms of the condition can include the return of stomach contents into the<br />mouth (regurgitation), being sick (vomiting) and poor weight gain.<br />Children and adolescents over 4 years of age<br />&bull; Ulcers which are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If your child has this<br />condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer<br />to heal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take AcilocTM<br />&bull; If you are allergic (hypersensitive) to omeprazole or any of the other ingredients of<br />AcilocTM.<br />&bull; If you are allergic to medicines containing other proton pump inhibitors (eg pantoprazole,<br />lansoprazole, rabeprazole, esomeprazole.<br />&bull; If you are taking a medicine containing nelfinavir (used for HIV infection)<br />If you are not sure, talk to your doctor or pharmacist before taking AcilocTM.<br />Take special care with AcilocTM<br />AcilocTM may hide the symptoms of other diseases. Therefore, if any of the following happen<br />to you before you start taking AcilocTM or while you are taking it, talk to your doctor straight<br />away:<br />&bull; You lose a lot of weight for no reason and have problems swallowing.<br />&bull; You get stomach pain or indigestion.<br />&bull; You begin to vomit food or blood.<br />&bull; You pass black stools (blood-stained faeces).<br />&bull; You experience severe or persistent diarrhoea, as omeprazole has been associated with a<br />small increase in infectious diarrhoea.<br />&bull; You have severe liver problems.<br />If you take AcilocTM on a long-term basis (longer than 1 year) your doctor will probably keep<br />you under regular surveillance. You should report any new and exceptional symptoms and<br />circumstances whenever you see your doctor.<br />Taking a proton pump inhibitor like AcilocTM, especially over a period of more than one year,<br />may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you<br />have osteoporosis or if you are taking corticosteroids (which can increase the risk of<br />osteoporosis).<br />Recent reports revealed an increased number of cases diagnosed with clostridium difficileassociated<br />diarrhea (CDAD). In certain number of studies, both conditions were found to be<br />significantly associated with the use of PPIs in hospitalized or non-hospitalized patients.<br />However, some studies did not find link between the CDAD with PPIs administration<br />although the influencing factors are controlled.<br />Observational studies found association between use of PPIs and development of CDAD. All<br />studies discussed the rate and risk of CDAD among PPIs users. It was clearly stated in some<br />studies that CDAD is more likely to be associated with PPIs consumption, however, some<br />studies indicated that the risk measurements do not yield a significant association between<br />CDAD and PPIs. The duration of therapy with PPIs found to be unrelated to CDAD episodes.<br />Seek immediate care if you use PPIs and develop diarrhea that does not improve. This may<br />be a sign of Clostridium difficile-associated diarrhea (CDAD).<br />Do not stop taking your prescription PPI drug without talking to your healthcare professional.<br />Taking other medicines<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines, including medicines obtained without a prescription. This is because AcilocTM can<br />affect the way some medicines work and some medicines can have an effect on AcilocTM.<br />Do not take AcilocTM if you are taking a medicine containing nelfinavir (used to treat HIV<br />infection).<br />Tell your doctor or pharmacist if you are taking any of the following medicines:<br />&bull; Ketoconazole, itraconazole or voriconazole (used to treat infections caused by a fungus).<br />&bull; Digoxin (used to treat heart problems).<br />&bull; Diazepam (used to treat anxiety, relax muscles or in epilepsy).<br />&bull; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor<br />you when you start or stop taking AcilocTM.<br />&bull; Medicines that are used to thin your blood, such as warfarin or other vitamin K blockers.<br />Your doctor may need to monitor you when you start or stop taking AcilocTM.<br />&bull; Rifampicin (used to treat tuberculosis).<br />&bull; Atazanavir (used to treat HIV infection).<br />&bull; Tacrolimus (in cases of organ transplantation).<br />&bull; St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression).<br />&bull; Cilostazol (used to treat intermittent claudication).<br />&bull; Saquinavir (used to treat HIV infection).<br />&bull; Clopidogrel (used to prevent blood clots (thrombi).<br />If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as<br />AcilocTM to treat ulcers caused by Helicobacter pylori infection, it is very important that you<br />tell your doctor about any other medicines you are taking.<br />Taking AcilocTM with food and drink<br />You can take your capsules with food or on an empty stomach.<br />Pregnancy and breast-feeding<br />Before taking AcilocTM, tell your doctor if you are pregnant or trying to get pregnant. Your<br />doctor will decide whether you can take AcilocTM during this time.<br />Your doctor will decide whether you can take AcilocTM if you are breast-feeding.<br />Driving and using machines<br />AcilocTM is not likely to affect your ability to drive or use any tools or machines.<br />Side effects such as dizziness and visual disturbances may occur (see section 4). If affected,<br />you should not drive or operate machinery.<br />Important information about some of the ingredients of AcilocTM<br />AcilocTM capsules contain lactose. If you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor before taking this medicinal product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take AcilocTM exactly as your doctor has told you. You should check with your<br />doctor or pharmacist if you are not sure.<br />Your doctor will tell you how many capsules to take and how long to take them for. This will<br />depend on your condition and how old you are.<br />The usual doses are given below.<br />Adults:<br />To treat symptoms of GORD such as heartburn and acid regurgitation:<br />&bull; If your doctor has found that your food pipe (gullet) has been slightly damaged, the usual<br />dose is 20 mg once a day for 4-8 weeks. Your doctor may tell you to take a dose of 40 mg for<br />a further 8 weeks if your gullet has not yet healed.<br />To treat ulcers in the upper part of the intestine (duodenal ulcer):<br />&bull; The usual dose is 20 mg once a day for 2 weeks. Your doctor may tell you to take the same<br />dose for a further 2 weeks if your ulcer has not yet healed.<br />&bull; If the ulcer do not fully heal, the dose can be increased to 40 mg once a day for 4 weeks.<br />To treat ulcers in the stomach (gastric ulcer):<br />&bull; The usual dose is 20 mg once a day for 4 weeks. Your doctor may tell you to take the same<br />dose for a further 4 weeks if your ulcer has not yet healed.<br />&bull; If the ulcer do not fully heal, the dose can be increased to 40 mg once a day for 8 weeks.<br />To prevent the duodenal and stomach ulcers from coming back:<br />&bull; The usual dose is 20 mg once a day. Your doctor may increase the dose to 40 mg once a<br />day.<br />To treat duodenal and stomach ulcers caused by NSAIDs (Non-Steroidal Anti-Inflammatory<br />Drugs):<br />&bull; The usual dose is 20 mg once a day for 4&ndash;8 weeks.<br />To prevent duodenal and stomach ulcers if you are taking NSAIDs<br />&bull; The usual dose is 20 mg once a day.<br />To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:<br />&bull; The usual dose is 20 mg AcilocTM twice a day for one week.<br />&bull; Your doctor will also tell you to take two antibiotics among amoxicillin, clarithromycin and<br />metronidazole.<br />To treat too much acid in the stomach caused by a growth in the pancreas (Zollinger-<br />Ellison syndrome):<br />&bull; The usual dose is 60 mg daily.<br />&bull; Your doctor will adjust the dose depending on your needs and will also decide how long<br />you need to take the medicine for.</p><p>Children:<br />To treat symptoms of GORD such as heartburn and acid regurgitation:<br />&bull; Children over 1 year of age and with a body weight of more than 10 kg may take AcilocTM.<br />The dose for children is based on the child&rsquo;s weight and the doctor will decide the correct<br />dose.<br />To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:<br />&bull; Children aged over 4 years may take Aciloc&trade;. The dose for children is based on the child&rsquo;s<br />weight and the doctor will decide the correct dose.<br />&bull; Your doctor will also prescribe two antibiotics called amoxicillin and clarithromycin for<br />your child.<br />Taking this medicine<br />&bull; It is recommended that you take your capsules in the morning.<br />&bull; You can take your capsules with food or on an empty stomach.<br />&bull; Swallow your capsules whole with half a glass of water. Do not chew or crush the capsules.<br />This is because the capsules contain coated pellets which stop the medicine from being<br />broken down by the acid in your stomach. It is important not to damage the pellets.<br />What to do if you or your child have trouble swallowing the capsules<br />&bull; If you or your child have trouble swallowing the capsules:<br />- Open the capsules and swallow the contents directly with half a glass of water or put the<br />contents into a glass of still (non-fizzy) water, any acidic fruit juice (e.g. apple, orange or<br />pineapple) or apple sauce.<br />- Always stir the mixture just before drinking it (the mixture will not be clear). Then drink the<br />mixture straight away or within 30 minutes.<br />- To make sure that you have drunk all of the medicine, rinse the glass very well with half a<br />glass of water and drink it. The solid pieces contain the medicine do not chew or crush them.<br />If you take more AcilocTM than you should<br />If you take more AcilocTM than prescribed by your doctor, talk to your doctor or pharmacist<br />straight away.<br />If you forget to take AcilocTM<br />If you forget to take a dose, take it as soon as you remember it. However, if it is almost time<br />for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten<br />dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, AcilocTM can cause side effects, although not everybody gets them.<br />If you notice any of the following rare but serious side effects, stop taking AcilocTM and<br />contact a doctor immediately:<br />&bull; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or<br />difficulties in swallowing (severe allergic reaction).<br />&bull; Reddening of the skin with blisters or peeling. There may also be severe blisters and<br />bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson<br />syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.<br />&bull; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.<br />Other side effects include:<br />Common side effects (affects 1 to 10 users in 100)<br />&bull; Headache. &bull; Effects on your stomach or gut: diarrhoea, stomach pain, constipation,<br />wind (flatulence). &bull; Feeling sick (nausea) or being sick (vomiting).<br />Uncommon side effects (affects 1 to 10 users in 1,000)<br />&bull; Swelling of the feet and ankles. &bull; Disturbed sleep (insomnia).<br />&bull; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.<br />&bull; Spinning feeling (vertigo).<br />&bull; Changes in blood tests that check how the liver is working.<br />&bull; Skin rash, lumpy rash (hives) and itchy skin.<br />&bull; Generally feeling unwell and lacking energy.<br />Rare side effects (affects 1 to 10 users in 10,000)<br />&bull; Blood problems such as a reduced number of white cells or platelets. This can cause<br />weakness, bruising or make infections more likely.<br />&bull; Allergic reactions, sometimes very severe, including swelling of the lips, tongue and throat,<br />fever, wheezing.<br />&bull; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and<br />cramps. &bull; Feeling agitated, confused or depressed. &bull; Taste changes.<br />&bull; Eyesight problems such as blurred vision.<br />&bull; Suddenly feeling wheezy or short of breath (bronchospasm).<br />&bull; Dry mouth. &bull; An inflammation of the inside of the mouth.<br />&bull; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.<br />&bull; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.<br />&bull; Hair loss (alopecia). &bull; Skin rash on exposure to sunshine.<br />&bull; Joint pains (arthralgia) or muscle pains (myalgia).<br />&bull; Severe kidney problems (interstitial nephritis). &bull; Increased sweating.<br />Very rare side effects (affects less than 1 user in 10,000)<br />&bull; Changes in blood count including agranulocytosis (lack of white blood cells).<br />&bull; Aggression. &bull; Seeing, feeling or hearing things that are not there (hallucinations).<br />&bull; Severe liver problems leading to liver failure and inflammation of the brain.<br />&bull; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a<br />high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal<br />necrolysis). &bull; Muscle weakness. &bull; Enlarged breasts in men.<br />Not known (frequency cannot be estimated from the available data)<br />&bull; If you are on AcilocTM for more than three months it is possible that the levels of magnesium<br />in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle<br />contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of<br />these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a<br />reduction in potassium or calcium levels in the blood. Your doctor may decide to perform<br />regular blood tests to monitor your levels of magnesium.<br />AcilocTM may in very rare cases affect the white blood cells leading to immune deficiency.<br />If you have an infection with symptoms such as fever with a severely reduced general<br />condition or fever with symptoms of a local infection such as pain in the neck, throat or<br />mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a<br />lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for<br />you to give information about your medicine at this time.<br />Do not be concerned by this list of possible side effects. You may not get any of them. If any<br />of the side effects get serious, or if you notice any side effects not listed in this leaflet, please<br />tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &deg;C.<br />&bull; Do not use Aciloc&trade; after the expiry date which is stated on the pack after EXP.<br />&bull; Store this blister in the original package.<br />&bull; Medicines should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will help to<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is omeprazole. AcilocTM hard gastro-resistant capsules (gastro-resistant<br />capsules) contain 20 mg or 40 mg of omeprazole.<br />- The other ingredients are mannitol, sucrose, disodium hydrogen phosphate, sodium lauryl<br />sulphate, lactose, calcium carbonate, hydroxy propyl methyl cellulose, methacrylic acid<br />L30D, propylene glycol, diethyl pthalate, cetyl alcohol, sodium hydroxide, tween 80,<br />PVPK-30, talc, titanium dioxide, erythrosine (FD&amp;C red no.3), quinoline yellow (D&amp;C<br />yellow no.10), brilliant blue FCF (FD&amp;C Blue no.1 ), allura red (FD&amp;C red no.40), sunset<br />yellow (FD&amp;C yellow no.6) and gelatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • AcilocTM 20 mg capsules: A brown opaque cap and light brown opaque body, hard gelatin
capsules printed with 'Jamjoom' on cap and 'Aci 20' on body in black, filled with white to pale
yellow colored spherical pellets.
• AcilocTM 40 mg capsules: A brown opaque cap and light brown opaque body, hard gelatin
capsules printed with 'Jamjoom' on cap and 'Aci 40' on body in black, filled with white to pale
yellow colored spherical pellets.
Aciloc™ 20 mg comes in packs of 7 & 14 & 28 capsules.
Aciloc™ 40 mg comes in packs of 7 & 14 & 28 capsules.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Ltd., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;يحتوي أسيلوك على أوميبرازول كمادة فعالة وهي تنتمي إلى فئة من الأدوية تسمى &quot;مثبطات مضخة البروتون&quot;<br />وهي تعمل على تقليل كمية الحمض الذي تنتجه المعدة.<br />لعلاج الحالات الآتية: &trade; يستخدم أسيلوك<br />للبالغين:<br />- الارتجاع المعدي المريئي حيث يهرب الحمض من داخل المعدة إلى المرئ (قناة تصل بين المعدة والحلق) مما<br />يسبب الألم والالتهاب وحرقة المعدة.<br />- قرحة في الجزء العلوي من الأمعاء (الإثنا عشر) أو المعدة.<br />- القرح التي تسببها عدوى بكتيريا تسمى (هيليكوباكتر بايلوري). إذا كنت مصابا بهذه الحالة فمن الممكن أن يصف<br />الطبيب لك مضادا حيويا لعلاج العدوى ومن ثم يمكن للقرحة ان تلتئم.<br />يمكن لأسيلوكأن يوقف - القرح التي تسببها فئة من الأدوية تسمى الأدوية غير الستيرودية والمضادة للالتهاب .<br />تكون القرح إذا كنت تستخدم الأدوية غير الستيرودية والمضادة للالتهاب.<br />- زيادة إفراز الحمض في المعدة الذي يسببه ورم في البنكرياس (متلازمة زولينجر إليسون).<br />للأطفال:<br />الأطفال الأكبر من عام و يزنون ۱۰ كجم أو أكثر<br />- الارتجاع المعدي المريئي حيث يهرب الحمض من داخل المعدة إلى المرئ (قناة تصل بين المعدة والحلق) مما<br />يسبب الألم والالتهاب وحرقة المعدة.<br />قد تشتمل الأعراض عند الأطفال على ارتجاع محتوى المعدة داخل الفم (الاجترار)، الشعور بالغثيان (القئ)،<br />انخفاض معدل زيادة الوزن.<br />الأطفال الأكبر والمراهقين الأكبر من ٤ أعوام<br />- القرح التي تسببها عدوى بكتيريا تسمى (هيليكوباكتر بايلوري). إذا كان طفلك مصابا بهذه الحالة فمن الممكن أن<br />يصف الطبيب له مضادا حيويا لعلاج العدوى ومن ثم يمكن للقرحة ان تلتئم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم أسيلوك إذا:<br />&nbsp;- إذا كنت تعاني من فرط الحساسية ضد أوميبرازول أو أي مكون آخر من مكونات أسيلوك<br />- إذا كان لديك حساسية تجاه أي دواء آخر يحتوي علي مثبطات مضخة البروتون مثل بانتوبرازول، لانسوبرازول،<br />رابيبرازول، ايسوميبرازول.<br />- إذا كنت تستخدم دواء يحتوي علي مادة نيلفينافير [تستخدم في حالات فيروس نقص المناعة المكتسب (الإيدز)].<br />&trade; إذا كنت غير متأكد استشر طبيبك أو الصيدلي قبل استخدامك أسيلوك<br />استخدم أسيلوك بحذر إذا:<br />من الممكن أن يخفي أسيلوك أعراض الأمراض الأخرى ولذلك إذا حدث لك أي شئ من الأشياء التالية بمجرد بدء&nbsp;<br />استخدام الدواء أو أثناء استخدامه استشر طبيبك علي الفور:<br />- لاحظت فقدان الوزن بدون سبب ومشاكل في البلع.<br />- ألم في المعدة او عسر الهضم.<br />- إذا بدأت في تقيؤ الطعام او الدم.<br />- كان لون البراز أسود (براز مخضب بالدم).<br />- إذا أصبت بإسهال شديد أو مستمر حيث أن أوميبرازول يكون مصحوب بزيادة في حدوث الإسهال المعدي.<br />- كان لديك مشاكل حادة في الكبد.<br />على المدى الطويل ، خصوصا لو كان ذلك لفترة أطول من عام، فمن المحتمل ان يضعك &trade; إذا قمت باستخدام أسيلوك<br />الدكتور تحت الملاحظة المنتظمة باستمرار. يجب عليك إبلاغ الطبيب عند زيارته عن أي أعراض أو ظروف جديدة<br />أو استثنائية.<br />أظهرت التقارير الأخيرة زيادة في عدد الحالات التي تم تشخيصها مع المطثية العسيرة المصحوبة بالإسهال<br />في عدد معين من الدراسات، تم العثور على كل من الشروط التي يجب أن يرتبط بشكل كبير مع استخدام .(CDAD)<br />مثبطات مضخة البروتون في المرضى في المستشفى أو في غير المستشفيات. ومع ذلك، فإن بعض الدراسات لم تجد<br />مع إستخدام مثبطات مضخة البروتون على الرغم من تثبيت العوامل المؤثرة. CDAD صلة بين<br />ناقشت جميع الدراسات .CDAD وجدت الدراسات الرصدية ارتباط بين استخدام مثبطات مضخة البروتون وتطور<br />CDAD بين مستخدمي مثبطات مضخة البروتون. وذكر بوضوح في بعض الدراسات أن CDAD معدل وخطر<br />من المرجح أن تترافق مع استهلاك مثبطات مضخة البروتون، ومع ذلك، أشارت بعض الدراسات إلى أن قياسات<br />و مثبطات مضخة البروتون. ووجد أن لا علاقة بين مدة العلاج مع CDAD الخطر لم تسفر وجود صلة واضحة بين<br />.CDAD مثبطات مضخة البروتون و نوبات<br />التماس الرعاية الفورية إذا كنت تستخدم مثبطات مضخة البروتون وتطور الإسهال الذي لا يتحسن. فقد يكون هذا<br />.(CDAD) علامة على المطثية العسيرة المصحوبة بالإسهال<br />الموصوفة لك دون التحدث الى مقدم الرعاية الصحية (PPI) لا تتوقف عن استخدام مثبطات مضخة البروتون<br />الخاص بك.<br />تناول الأدوية الأخرى<br />يرجى إخبار الطبيب حول أي أدوية أخرى تتناولها حاليا أو تناولتها منذ فترة وجيزة بما في ذلك الأدوية التي قمت<br />من الممكن أن يؤثر في طريقة عمل بعض الأدوية الأخرى &trade; باستخدامها دون وصفة طبيبة وهذا بسبب أن أسيلوك<br />&trade; كما يمكن لبعض الأدوية الأخرى أن تؤثر في طريقة عمل أسيلوك<br />إذا كنت تستخدم دواء يحتوي على مادة نيلفينافير [تستخدم في حالات فيروس نقص المناعة &trade; لا تتناول أسيلوك<br />المكتسب (الإيدز)].<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:<br />- كيتوكونازول، ايتراكونازول، فوريكونازول (تستخدم لعلاج عدوى الفطريات).<br />- ديجوكسين (يستخدم لعلاج مشاكل القلب).<br />- ديازيبام (يستخدم في علاج القلق، باسط للعضلات، الصرع).<br />- فينيتوين (يستخدم في علاج الصرع). إذا كنت تستخدم فينيتوين سيحتاج الطبيب لوضعك تحت الملاحظة بعد توقفك<br />&trade; عن تناول أسيلوك<br />- الأدوية التي تستخدم لتمييع الدم ومنع تخثره مثل الوارفارين أو حاصرات فيتامين ك الأخرى. سيحتاج الطبيب<br />&trade; لوضعك تحت الملاحظة بعد توقفك عن تناول أسيلوك<br />- ريفامبيسين (يستخدم لعلاج السل).<br />- أتازانافير [يستخدم في حالات فيروس نقص المناعة المكتسب (الإيدز)].<br />- تاكروليماس (في حالات زرع الأعضاء).<br />- نبتة سنات جونز او حشيشة القلب (هايبريكام بيرفوراتام) (تستخدم في علاج الاكتئاب البسيط).<br />- سيلوستازول (يستخدم في علاج العرج المتقطع).<br />- ساكوينافير[يستخدم في حالات فيروس نقص المناعة المكتسب (الإيدز)].<br />- كلوبيدوجريل (يمنع تكون جلطات الدم).<br />لعلاج القرحة الناتج &trade; إذا وصف لك الطبيب مضاد حيوي مثل الأموكسيسيللين أو الكلاريثرومايسين بجانب أسيلوك<br />عن بكتيريا الهيليكوباتر بايلوري، من المهم جدا أن تخبر طبيبك حول الأدوية الأخرى التي تتناولها.<br />مع الطعام والشراب &trade; تناول أسيلوك<br />يمكنك أن تتناول كبسولات الدواء مع الطعام أو على معدة خالية.<br />الحمل والإرضاع<br />قبل استخدام أسيلوك&nbsp;يرجى إخبار الطبيب إذا كنتِ حاملاً أو تخططين للحمل. سيقرر الطبيب إمكانية تناول أسيلوك &trade; من عدمه في هذا الوقت.<br />سيقرر الطبيب إمكانية تناول أسيلوك من عدمه إذا كنتِ مرضعة.&nbsp;&nbsp;<br />قيادة المركبات وتشغيل الآلات<br />على قدرتك على قيادة المركبات أو تشغيل المعدات. &trade; من غير المحتمل أن يؤثر أسيلوك<br />قد تحدث بعض الآثار الجانبية مثل الدوخة أو اضطراب في الرؤية وفي هذه الحالات يجب الامتناع عن قيادة<br />السيارات أو تشغيل الآلات.<br />معلومات هامة حول بعض مكونات أسيلوك<br />تحتوي كبسولات أسيلوك علي اللاكتوز. إذا كان قد تم إخبارك بواسطة طبيبك عن أنك لديك حساسية ضد بعض&nbsp;<br />السكريات فيجب عليك استشارة الطبيب قبل استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب أن يكون تناول أسيلوك وفقا لما يخبرك به الطبيب. يجب عليك مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدا.&nbsp;&nbsp;<br />سيخبرك الطبيب عن عدد الكبسولات التي ستتناولها والمدة التي ستتناول فيها الدواء. سيتوقف ذلك على حالتك وعلى<br />عمرك.<br />الجرعات الاعتيادية موضحة بالأسفل.<br />البالغين:<br />لعلاج أعراض الارتجاع المعدي المريئي مثل حرقة المعدة واجترار الحمض:<br />- إذا وجد طبيبك أن قناة الطعام (المرئ) قد أصابها بعض التلف تكون الجرعة الاعتيادية هي ۲۰ ملجم مرة واحدة في<br />۸ أسابيع. من الممكن أن يصف لك الطبيب جرعة ٤۰ ملجم لمدة ۸ أسابيع أخرى في حالة عدم التئام - اليوم ولمدة ٤<br />المرئ.<br />لعلاج قرح الجزء العلوي من الأمعاء (قرحة الاثنا عشر):<br />- الجرعة الاعتيادية هي ۲۰ ملجم مرة واحدة في اليوم ولمدة أسبوعين. من الممكن أن يصف لك الطبيب نفس<br />الجرعة لمدة أسبوعين آخرين في حالة عدم التئام القرحة.<br />- إذا لم تلتئم القرحة بشكل كامل يمكن زيادة الجرعة إلى ٤۰ ملجم مرة واحدة في اليوم ولمدة ٤ أسابيع.<br />لعلاج قرحة المعدة:<br />- الجرعة الاعتيادية هي ۲۰ ملجم مرة واحدة في اليوم ولمدة ٤ أسابيع. من الممكن أن يصف لك الطبيب نفس<br />الجرعة لمدة ٤ أسابيع أخرى في حالة عدم التئام القرحة.<br />- إذا لم تلتئم القرحة بشكل كامل يمكن زيادة الجرعة إلى ٤۰ ملجم مرة واحدة في اليوم ولمدة ۸ أسابيع.<br />لمنع عودة حدوث قرحة المعدة والاثني عشر:<br />- الجرعة الاعتيادية هي ۲۰ ملجم مرة واحدة يوميا. قد يزيد الطبيب الجرعة لتصبح ٤۰ ملجم مرة واحدة يوميا.<br />لعلاج قرحة المعدة والاثنى عشر التي تتسبب فيها الأدوية غير الستيرودية والمضادة للالتهاب:<br />۸ أسابيع. - - الجرعة الاعتيادية هي ۲۰ ملجم مرة واحدة يوميا لمدة ٤<br />لمنع عودة حدوث قرحة المعدة والاثني عشر التي تتسبب فيها الأدوية غير الستيرودية والمضادة<br />للالتهاب:<br />- الجرعة الاعتيادية هي ۲۰ ملجم مرة واحدة يوميا<br />لعلاج القرح التي تتسبب فيها بكتيريا هيليكوباكتر بايلوري ولمنع عودة حدوثها مرة أخرى:<br />- الجرعة الاعتيادية هي ۲۰ ملجم مرتين يوميا ولمدة أسبوع.<br />- سيصف لك الطبيب أيضا استخدام اثنين من المضادات الحيوية: أموكسيسيللين، كلاريثرومايسن، ميترونيدازول.<br />لعلاج فرط إفراز الحمض داخل المعدة بسبب ورم في البنكرياس (متلازمة زولينجر إيليسون):<br />- الجرعة الاعتيادية هي ٦۰ ملجم يوميا<br />- سيقوم الطبيب بتعديل الجرعة وفقا لحالتك واحتياجك وسيحدد أيضا الفترة التي ستستمر في تناول الدواء خلالها.</p><p>الأطفال:<br />لعلاج أعراض الارتجاع المعدي المريئي مثل حرقة المعدة واجترار الحمض:<br />تعتمد الجرعة في هذه الحالة علي .&trade; - الأطفال الاكبر من عام ويزنون اكثر من ۱۰ كجم من الممكن أن يتعاطوا أسيلوك<br />وزن الطفل ويقوم الطبيب بتحديد الجرعة الصحيحة.<br />لعلاج القرح التي تتسبب فيها بكتيريا هيليكوباكتر بايلوري ولمنع عودة حدوثها مرة أخرى:<br />الأطفال الأكبر من ٤ أعوام من الممكن أن يتعاطوا أسيلوك تعتمد الجرعة في هذه الحالة علي وزن الطفل ويقوم&nbsp;<br />الطبيب بتحديد الجرعة الصحيحة.<br />- سيصف الطبيب لطفلك استخدام اثنين من المضادات الحيوية هما أموكسيسيللين، كلاريثرومايسن.<br />تناول هذا الدواء<br />- ينصح بتناول هذه الكبسولات عند الصباح.<br />- يمكنك تناول الكبسولات مع الطعام أو على معدة خالية.<br />- ابلع كامل الكبسولة مع نصف كوب من الماء. لا تمضغ أو تطحن الكبسولة وهذا بسبب أن هذه الكبسولة تحتوي على<br />كريات مغلفة تحمي الدواء من أن يتم تكسيره بواسطة الحمض في المعدة. من المهم أن لا تقوم بإتلاف هذه الكريات.<br />ماذا تفعل إذا كان لديك أو لدى طفل مشاكل في بلع الكبسولات؟<br />إذا كان لديك أو لدى طفلك مشاكل في بلع الكبسولات.<br />- افتح الكبسولة وابتلع محتوياتها مباشرة مع نصف كوب من الماء، أو ضع محتوياتها في كوب من الماء (غير الغازي)<br />أو أي عصير حامضي مثل البرتقال أو التفاح أو الأناناس أو صوص التفاح.<br />- دائما قم بتقليب الخليط (الخليط لن يكون نقيا) ثم قم بشرب الخليط مباشرة أو خلال ۳۰ دقيقة.<br />- للتأكد من أنك قمت ببلع كامل كمية الدواء قم بشطف الكوب بنصف كوب من الماء بشكل جيد ثم اشربه. الأجزاء<br />الصلبة تكون محتوية علي دواء.لا تقم بتحطيمها أو مضغها.<br />إذا تناولت أسيلوك بكمية أكثر مما ينبغي&nbsp;&nbsp;<br />إذا تناولت أسيلوك بكمية أكثر مما وصفه لك الطبيب، اتصل بطبيبك أو الصيدلي فوراً.&nbsp;&nbsp;<br />&nbsp;إذا نسيت أن تتناول أسيلوك<br />إذا نسيت موعد الجرعة فقم بتناولها فور أن تتذكر، فإذا كان موعد الجرعة التالية قد حان فقم بالغاء الجرعة التي نسيتها.<br />لا تتناول ضعف الجرعة لكي تعوض الجرعة الفائتة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن ل أسيلوك أن يتسبب في تأثيرات جانبية ولكنها لا تصيب كل الأشخاص. &trade; كما هو الحال مع كل الأدوية.<br />&nbsp;إذا لا حظت ظهور أي من الأعراض الجانبية التالية النادرة والخطيرة توقف عن استخدام أسيلوكواتصل بالطبيب<br />على الفور:<br />- صفير مفاجئ، تورم (الشفاة، اللسان، الحلق، الجسم)، طفح جلدي، إغماء، صعوبة في البلع (تفاعل تحسسي حاد).<br />- احمرار الجلد مع وجود بثور أو تقشر. من الممكن أيضا ان يكون هناك بثور حادة ونزيف في الشفاة، العيون، الفم،<br />الأنف، الأعضاء التناسلية. من الممكن أن يكون ذلك هو متلازمة ستيفين جونسون أو انحلال البشرة السمي.<br />- الجلد الأصفر، البول الداكن، الإجهاد من الممكن أن يكونوا أعراض لمشاكل في الكبد.<br />الآثار الجانبية الأخرى<br />۱۰ أشخاص من أصل ۱۰۰ يستخدمون الدواء) - شائعة ( يصاب بها من ۱<br />- الصداع. - تأثيرات علي المعدة أو الجهاز الهضمي: إسهال، ألم في المعدة، إمساك، ريح (انتفاخ).<br />- الشعور بالغثيان أو القئ.<br />۱۰ أشخاص من أصل ۱۰۰۰ يستخدمون الدواء) - غير شائعة (يصاب بها من ۱<br />- تورم القدم و الكاحل. - اضطراب النوم (الأرق).<br />- الدوخة، الشعور بالوخز (مثل وخز الإبر والدبابيس)، الشعور بالنعاس.<br />- الشعور بالدوار. - تغيرات في نتائج اختبارات الدم التي تدل على سلامة وظائف الكبد.<br />- طفح جلدي، طفح عُقدي (أرتيكاريا)، حكة في الجلد. - الشعور بالتعب وفقدان الطاقة.<br />۱۰ أشخاص من أصل ۱۰۰۰۰ يستخدمون الدواء) - نادرة (يصاب من ۱<br />- مشاكل في الدم مثل انخفاض عدد خلايا الدم البيضاء أو الصفائح الدموية. من الممكن أن يتسبب ذلك في الشعور<br />بالضعف، الكدمات، سهولة الإصابة بالعدوى.<br />- تفاعل تحسسي، يكون حادا في بعض الاحيان ويشمل تورم في (الشفاة، اللسان، الحلق)، حمى، صفير.<br />- انخفاض معدل الصوديوم في الدم وهو ما يمكن أن يتسبب في الضعف أو القئ أو تقلصات في العضلات.<br />- الشعور بالهياج أو التوتر أو الاكتئاب.<br />- تغيرات في حاسة التذوق. - مشاكل في الرؤية مثل عدم وضوح الرؤية.<br />- ضيق النفس مع الشعور بالصفير (انقباض في الشعب الهوائية).<br />- جفاف في الفم. - التهاب داخل الفم.<br />- الإصابة بعدوى تسمى &quot;القلاع&quot; والتي تصيب القناة الهضمية ويتسبب فيها أحد الفطريات.<br />- مشاكل في الكبد بما في ذلك الصفراء والتي تشمل اصفرار في الجلد وبول داكن والشعور بالتعب.<br />- سقوط الشعر (الصلع). - طفح جلدي عن التعرض لأشعة الشمس.<br />- آلام في المفاصل والعضلات. - مشاكل حادة في الكلى. - زيادة إفراز العرق.<br />نادرة جدا (يصاب بها أقل من ۱ من أصل ۱۰۰۰۰ شخص يستخدمون الدواء)<br />- تغيرات في عدد خلايا الدم بما في ذلك ما يسمى بندرة المحببات (نقص عدد خلايا الدم البيضاء).<br />- العدوانية. - رؤية أو سماع أو الشعور بأشياء غير موجودة (الهلوسة).<br />- مشاكل حادة في الكبد تؤدي إلى فشل في وظائف الكبد والتهاب في المخ.<br />- ظهور مفاجئ لطفح جلدي أو بثور أو تقشر في الجلد.من الممكن ان يكون ذلك مصحوبا بحمى شديدة وآلام في<br />المفاصل (حُمامى عديدة الأشكال، متلازمة ستيفن جونز، انحلال البشرة النخري)<br />- ضعف في العضلات. - تضخم في الثدي عند الرجال.<br />غير معروفة (لا يمكن توقع معدل تكرارها من البيانات المتاحة).<br />إذا كنت تتناول أسيلوك منذ أكثر من ۳ أشهر فمن الممكن ان يهبط مستوى الماغنسيوم في الدم. انخفاض مستوى&nbsp; -<br />الماغنسيوم يظهر علي شكل إجهاد ، انقباضات لا إرادية في العضلات، التوهان، تشنجات، دوخة، ازدياد معدل<br />ضربات القلب.<br />إذا كان لديك أحد هذه الأعراض أخبر طبيبك على وجه السرعة.<br />انخفاض مستوى الماغنسيوم في الدم قد يؤدي أيضا إلي انخفاض في مستويات الكالسيوم والبوتاسيوم. قد ينصحك<br />الطبيب بعمل فحوصات دورية للدم لمراقبة مستوى الماغنسيوم.<br />على خلايا الدم البيضاء بما يؤدي إلي نقص في المناعة. إذا كان لديك &trade; في بعض الحالات النادرة جدا قد يؤثر أسيلوك<br />عدوي مع اعراض مثل الحمى مع انخفاض حاد في الحالة العامة أو حمى مع أعراض عدوى موضعية مثل آلام في<br />الرقبة أو الحلق أو الفم أو صعوبة في التبول، يجب عليك استشارة الطبيب بأقصى سرعة ممكنة ولهذا فإن نقص خلايا<br />الدم البيضاء (ندرة المحببات) يمكن استبعاده عن طريق عمل اختبار أو تحليل للدم. من المهم أن تعطي معلومات حول<br />دوائك في هذا التوقيت.<br />لا تقلق من هذه القائمة الخاصة بالأعراض الجانبية فقد لا يصيبك أيا منها. إذا وصلت أيا من هذه الأعراض لدرجة<br />الخطورة أو لاحظت ظهور أعراض أخرى غير مذكورة في هذه النشرة، يرجى اخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيداً عن متناول و مرأى الأطفال .<br />&bull; يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />&bull; لا تستخدم أسيلوك بعد تاريخ انتهاء الصلاحية المدون على العبوة بعد.EXP<br />&bull; قم بتخزين الشريط داخل العلبة الأصلية.<br />&bull; لا ينبغي التخلص من الأدوية عبر بالوعات الصرف أو ضمن مخلفات المنزل.<br />اسأل الصيدلي الخاص بك عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحتوي كبسولات أسيلوك المقاومة للعصارة الهضمية علي المادة فعالة هي أوميبرازول.<br />۲۰ ملجم أو ٤۰ ملجم من الأوميبرازول.<br />- المكونات الأخرى هي: مانيتول، سكروز، ثنائي الصوديوم هيدروجين فوسفات، سلفات لوريل الصوديوم، لاكتوز،<br />بروبيلين جليكول، ثنائي اثيل ،L30D كربونات الكالسيوم، هيدروكسي بروبيل ميثيل السليلوز، حمض ميثاكريليك<br />التلك، ثاني أكسيد التيتانيوم ، ،PVPK-30 ، بثالات، كحول سيتيل، هيدروكسيد الصوديوم، توين ۸۰<br />،( أحمر رقم. ۱ FD&amp;C) أصفررقم. ۱۰ )، أزرق C &amp; D) أحمر رقم. ۳)، وأصفر الكينولين FD&amp;C) إيريثروثينِ<br />أحمر رقم. ٦) و جيلاتين. FD&amp;C) أحمر رقم. ٤۰ )، أصفر FD&amp;C) الأحمر اليورا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">كبسولات أسيلوك20 ملجم ذات جزء علوي بني اللون غير شفاف والجزء الآخر السفلي بني فاتح اللون غير شفاف مطبوع عليها كلمة &quot;Jamjoom&quot; على الجزء العلوي وكلمة &quot;Aci20&quot;على الجزء السفلي باللون الأسود.<br />كبسولات جيلاتينية صلبة مملوءة بحبيبات كروية لونها أبيض إلى أصفر فاتح.</p><p style="text-align:right">كبسولات أسيلوك 40 ملجم ذات جزء علوي بني اللون غير شفاف والجزء الآخر السفلي بني فاتح اللون غير شفاف مطبوع عليها كلمة &quot;Jamjoom&quot; على الجزء العلوي وكلمة &quot;Aci40&quot;على الجزء السفلي باللون الأسود.<br />كبسولات جيلاتينية صلبة مملوءة بحبيبات كروية لونها أبيض إلى أصفر فاتح.</p><p style="text-align:right"><br />أسيلوك 20ملجم, عبوة تحتوي على7,14,28 كبسولة.&nbsp;<br />أسيلوك 40ملجم, عبوة تحتوي على7,14,28 كبسولة.&nbsp;<br />قد لا تكون كل أحجام العبوات مطروحة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدوية المحدودة، جدة، المملكة العربية السعودية<br />- الهاتف: 608111-12-966+ فاكس :&nbsp;608222-12-966+<br />الموقع الإلكتروني:&nbsp;www.jamjoompharma.com&nbsp;<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />المركز الوطني للتيقظ و السلامة الدوائية<br />- فاكس: 7662-205-11-966+&nbsp;<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.<br />هاتف: 22228302-11-966+ تحويلة: 2317-2356-2353-2354-2334-2340<br />الهاتف المجاني: 8002490000<br />بريد إلكتروني:&nbsp;npc.drug@sfda.gov.sa<br />الموقع الالكتروني:&nbsp;www.sfda.gov.sa/npc<br />&bull; دول الخليج الأخرى:<br />الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aciloc 40 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 40 mg Omeprazole.
Excipients:
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule, hard (capsule).
Hard gelatine capsules with an opaque reddish-brown body, marked 40 and an opaque reddishbrown
cap marked A/OL, containing enteric coated pellets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aciloc 40 capsules are indicated for:<br />Adults<br />&bull; Treatment of duodenal ulcers<br />&bull; Prevention of relapse of duodenal ulcers<br />&bull; Treatment of gastric ulcers<br />&bull; Prevention of relapse of gastric ulcers<br />&bull; In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic<br />ulcer disease<br />&bull; Treatment of NSAID-associated gastric and duodenal ulcers<br />&bull; Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk<br />&bull; Treatment of reflux oesophagitis<br />&bull; Long-term management of patients with healed reflux oesophagitis</p><p>&bull; Treatment of symptomatic gastro-oesophageal reflux disease<br />&bull; Treatment of Zollinger-Ellison syndrome<br />Paediatric use<br />Children over 1 year of age and 10 kg<br />&bull; Treatment of reflux oesophagitis<br />&bull; Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease<br />Children and adolescents over 4 years of age<br />&bull; In combination with antibiotics in treatment of duodenal ulcer caused by H. pylori</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology in adults<br />Treatment of duodenal ulcers<br />The recommended dose in patients with an active duodenal ulcer is Aciloc 20 mg once daily. In<br />most patients healing occurs within two weeks. For those patients who may not be fully healed<br />after the initial course, healing usually occurs during a further two weeks treatment period. In<br />patients with poorly responsive duodenal ulcer Aciloc 40 mg once daily is recommended and<br />healing is usually achieved within four weeks.<br />Prevention of relapse of duodenal ulcers<br />For the prevention of relapse of duodenal ulcer in H. pylori negative patients or when H.<br />pylori eradication is not possible the recommended dose is Aciloc 20 mg once daily. In some<br />patients a daily dose of 10 mg may be sufficient. In case of therapy failure, the dose can be<br />increased to 40 mg.<br />Treatment of gastric ulcers<br />The recommended dose is Aciloc 20 mg once daily. In most patients healing occurs within four<br />weeks. For those patients who may not be fully healed after the initial course, healing usually<br />occurs during a further four weeks treatment period. In patients with poorly responsive gastric<br />ulcer Aciloc 40 mg once daily is recommended and healing is usually achieved within eight<br />weeks.</p><p>Prevention of relapse of gastric ulcers<br />For the prevention of relapse in patients with poorly responsive gastric ulcer the recommended<br />dose is Aciloc 20 mg once daily. If needed the dose can be increased to Aciloc 40 mg once daily.<br />H. pylori eradication in peptic ulcer disease<br />For the eradication of H. pylori the selection of antibiotics should consider the individual patient&#39;s<br />drug tolerance, and should be undertaken in accordance with national, regional and local<br />resistance patterns and treatment guidelines.<br />&bull; Aciloc 20 mg + clarithromycin 500 mg + amoxicillin 1,000 mg, each twice daily for one week, or<br />&bull; Aciloc 20 mg + clarithromycin 250 mg (alternatively 500 mg) + metronidazole 400 mg (or 500<br />mg or tinidazole 500 mg), each twice daily for one week or<br />&bull; Aciloc 40 mg once daily with amoxicillin 500 mg and metronidazole 400 mg (or 500 mg or<br />tinidazole 500 mg), both three times a day for one week.<br />In each regimen, if the patient is still H. pylori positive, therapy may be repeated.<br />Treatment of NSAID-associated gastric and duodenal ulcers<br />For the treatment of NSAID-associated gastric and duodenal ulcers, the recommended dose is<br />Aciloc 20 mg once daily. In most patients healing occurs within four weeks. For those patients<br />who may not be fully healed after the initial course, healing usually occurs during a further four<br />weeks treatment period.<br />Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk<br />For the prevention of NSAID-associated gastric ulcers or duodenal ulcers in patients at risk (age&gt;<br />60, previous history of gastric and duodenal ulcers, previous history of upper GI bleeding) the<br />recommended dose is Aciloc 20 mg once daily.<br />Treatment of reflux oesophagitis<br />The recommended dose is Aciloc 20 mg once daily. In most patients healing occurs within four<br />weeks. For those patients who may not be fully healed after the initial course, healing usually<br />occurs during a further four weeks treatment period.<br />In patients with severe oesophagitis Aciloc 40 mg once daily is recommended and healing isusually achieved within eight weeks.<br />Long-term management of patients with healed reflux oesophagitis<br />For the long-term management of patients with healed reflux oesophagitis the recommended<br />dose is Aciloc 10 mg once daily. If needed, the dose can be increased to Aciloc 20-40 mg once<br />daily.<br />Treatment of symptomatic gastro-oesophageal reflux disease<br />The recommended dose is Aciloc 20 mg daily. Patients may respond adequately to 10 mg daily,<br />and therefore individual dose adjustment should be considered.<br />If symptom control has not been achieved after four weeks treatment with Aciloc 20 mg daily,<br />further investigation is recommended.<br />Treatment of Zollinger-Ellison syndrome<br />In patients with Zollinger-Ellison syndrome the dose should be individually adjusted and treatment<br />continued as long as clinically indicated. The recommended initial dose is Aciloc 60 mg daily. All<br />patients with severe disease and inadequate response to other therapies have been effectively<br />controlled and more than 90% of the patients maintained on doses of Aciloc 20-120 mg daily.<br />When dose exceed Aciloc 80 mg daily, the dose should be divided and given twice daily.<br />Posology in children<br />Children over 1 year of age and 10 kg<br />Treatment of reflux oesophagitis<br />Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease<br />The posology recommendations are as follows:</p><p><br />- 1 year of age&nbsp; (Weight 10-20 kg) 10 mg once daily. The dose can be increased to 20 mg once daily if needed<br />- 2 years of age (Weight &gt; 20 kg ) 20 mg once daily. The dose can be increased to 40 mg once daily if needed</p><p>&nbsp;</p><p>Reflux oesophagitis: The treatment time is 4-8 weeks.<br />Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux<br />disease: The treatment time is 2&ndash;4 weeks. If symptom control has not been achieved after 2&ndash;4<br />weeks the patient should be investigated further.<br />Children and adolescents over 4 years of age<br />Treatment of duodenal ulcer caused by H. pylori<br />When selecting appropriate combination therapy, consideration should be given to official<br />national, regional and local guidance regarding bacterial resistance, duration of treatment (most<br />commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents.<br />The treatment should be supervised by a specialist.<br />The posology recommendations are as follows:</p><p>(Weight 15&ndash;30 kg): Combination with two antibiotics: Aciloc 10 mg, amoxicillin 25 mg/kg body<br />weight and clarithromycin 7.5 mg/kg body weight are all administrated together two times daily for one week.<br />(Weight 31&ndash;40 kg): Combination with two antibiotics: Aciloc 20 mg, amoxicillin 750 mg and<br />clarithromycin 7.5 mg/kg body weight are all administrated two times daily for one week.<br />(Weight &gt; 40 kg): Combination with two antibiotics: Aciloc 20 mg, amoxicillin 1 g and<br />clarithromycin 500 mg are all administrated two times daily for one week.</p><p>Special populations<br />Impaired renal function<br />Dose adjustment is not needed in patients with impaired renal function (see section 5.2).<br />Impaired hepatic function<br />In patients with impaired hepatic function a daily dose of 10&ndash;20 mg may be sufficient</p><p>(see section 5.2).<br />Elderly (&gt; 65 years old)<br />Dose adjustment is not needed in the elderly (see section 5.2).<br />Method of administration<br />It is recommended to take Aciloc capsules in the morning, preferably without food, swallowed<br />whole with half a glass of water. The capsules must not be chewed or crushed.<br />For patients with swallowing difficulties and for children who can drink or swallow semi-solid food<br />Patients can open the capsule and swallow the contents with half a glass of water or after mixing<br />the contents in a slightly acidic fluid e.g., fruit juice or applesauce, or in non-carbonated water.<br />Patients should be advised that the dispersion should be taken immediately (or within 30 minutes)<br />and always be stirred just before drinking and rinsed down with half a glass of water.<br />Alternatively patients can suck the capsule and swallow the pellets with half a glass of water. The<br />enteric-coated pellets must not be chewed..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to Omeprazole, substituted benzimidazoles or to any of the excipients.
Omeprazole like other proton pump inhibitors (PPIs) must not be used concomitantly with
nelfinavir (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis. Co-administration of atazanavir with proton pump inhibitors is not recommended (see section 4.5).<br />If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load) is recommended in combination with an increase in the dose of<br />atazanavir to 400 mg with 100 mg of ritonavir; omeprazole 20 mg should not be exceeded.<br />Omeprazole, as all acid-blocking medicinal products, may reduce the absorption of vitamin B12<br />(cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced<br />body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.<br />Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with omeprazole, the<br />potential for interactions with medicinal products metabolised through CYP2C19 should be<br />considered. An interaction is observed between clopidogrel and omeprazole (see section 4.5). The<br />clinical relevance of this interaction is uncertain. As a precaution, concomitant use of omeprazole<br />and clopidogrel should be discouraged.<br />Severe hypomagnesaemia has been reported in patients treated with PPIs like omeprazole for at<br />least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such<br />as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they<br />may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved<br />after magnesium replacement and discontinuation of the PPI.<br />For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal<br />products that may cause hypomagnesaemia (e.g., diuretics), health care professionals should<br />consider measuring magnesium levels before starting PPI treatment and periodically during<br />treatment.<br />Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may<br />modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in<br />presence of other recognised risk factors. Observational studies suggest that proton pump<br />inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due&nbsp;to other risk factors. Patients at risk of osteoporosis should receive care according to current<br />clinical guidelines and they should have an adequate intake of vitamin D and calcium.<br />Subacute cutaneous lupus erythematosus (SCLE)<br />Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur,<br />especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should<br />seek medical help promptly and the health care professional should consider stopping Omeprazole.<br />SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with<br />other proton pump inhibitors.<br />Interference with laboratory tests<br />Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine<br />tumours. To avoid this interference, [nationally completed name] treatment should be stopped for<br />at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not<br />returned to reference range after initial measurement, measurements should be repeated 14 days<br />after cessation of proton pump inhibitor treatment.<br />Paediatric population<br />Some children with chronic illnesses may require long-term treatment although it is not<br />recommended.<br />Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal<br />infections such as Salmonella and Campylobacter and, in hospitalised patients, possibly<br />also Clostridium difficile (see section 5.1).<br />As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients<br />should be kept under regular surveillance.<br />Omeprazole contains sucrose and sodium<br />Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or<br />sucrose-isomaltase insufficiency should not take this medicinal product.<br />This medicinal product contains less than 1 mmol (23 mg) sodium per gastro-resistant hard<br />capsule, that is to say essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of Omeprazole on the pharmacokinetics of other active substances<br />Active substances with pH dependent absorption<br />The decreased intragastric acidity during treatment with Omeprazole might increase or decrease<br />the absorption of active substances with a gastric pH dependent absorption.<br />Nelfinavir, atazanavir<br />The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with<br />Omeprazole.<br />Concomitant administration of Omeprazole with nelfinavir is contraindicated (see section 4.3). Coadministration<br />of Omeprazole (40 mg once daily) reduced mean nelvinavir exposure by ca. 40%<br />and the mean exposure of the pharmacologically active metabolite M8 was reduced by ca. 75 &ndash;<br />90%. The interaction may also involve CYP2C19 inhibition.<br />Concomitant administration of Omeprazole with atazanavir is not recommended (see section 4.4).<br />Concomitant administration of Omeprazole (40 mg once daily) and atazanavir 300 mg/ritonavir<br />100 mg to healthy volunteers resulted in a 75% decrease of the atazanavir exposure. Increasing<br />the atazanavir dose to 400 mg did not compensate for the impact of Omeprazole on atazanavir<br />exposure. The co-administration of Omeprazole (20 mg once daily) with atazanavir 400<br />mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the<br />atazanavir exposure as compared to atazanavir 300 mg/ritonavir 100 mg once daily.<br />Digoxin<br />Concomitant treatment with Omeprazole (20 mg daily) and digoxin in healthy subjects increased<br />the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported. However caution<br />should be exercised when Omeprazole is given at high doses in elderly patients. Therapeutic<br />drug monitoring of digoxin should be then be reinforced.<br />Clopidogrel<br />In a crossover clinical study, clopidogrel (300 mg loading dose followed by 75 mg/day) alone and<br />with Omeprazole (80 mg at the same time as clopidogrel) were administered for 5 days. The<br />exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5)<br />when clopidogrel and Omeprazole were administered together. Mean inhibition of platelet</p><p>aggregation (IPA) was diminished by 47% (24 hours) and 30% (Day 5) when clopidogrel and<br />Omeprazole were administered together. In another study it was shown that administering<br />clopidogrel and Omeprazole at different times did not prevent their interaction that is likely to be<br />driven by the inhibitory effect of Omeprazole on CYP2C19. Inconsistent data on the clinical<br />implications of this PK/PD interaction in terms of major cardiovascular events have been reported<br />from observational and clinical studies.<br />Other active substances<br />The absorption of posaconazole, erlotinib, ketoconazol and itraconazol is significantly reduced<br />and thus clinical efficacy may be impaired. For posaconazol and erlotinib concomitant use should<br />be avoided.<br />Active substances metabolised by CYP2C19<br />Omeprazole is a moderate inhibitor of CYP2C19, the major Omeprazole metabolising enzyme.<br />Thus, the metabolism of concomitant active substances also metabolised by CYP2C19, may be<br />decreased and the systemic exposure to these substances increased. Examples of such drugs<br />are R-warfarin and other vitamin K antagonists, cilostazol, diazepam and phenytoin.<br />Cilostazol<br />Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased<br />Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by<br />29% and 69% respectively.<br />Phenytoin<br />Monitoring phenytoin plasma concentration is recommended during the first two weeks after<br />initiating Omeprazole treatment and, if a phenytoin dose adjustment is made, monitoring and a<br />further dose adjustment should occur upon ending Omeprazole treatment.<br />Unknown mechanism<br />Saquinavir<br />Concomitant administration of Omeprazole with saquinavir/ritonavir resulted in increased plasma<br />levels up to approximately 70% for saquinavir associated with good tolerability in HIV-infected<br />patients.</p><p>Tacrolimus<br />Concomitant administration of Omeprazole has been reported to increase the serum levels of<br />tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function<br />(creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.<br />Effects of other active substances on the pharmacokinetics of Omeprazole<br />Inhibitors CYP2C19 and/or CYP3A4<br />Since Omeprazole is metabolised by CYP2C19 and CYP3A4, active substances known to inhibit<br />CYP2C19 or CYP3A4 (such as clarithromycin and voriconazole) may lead to increased<br />Omeprazole serum levels by decreasing Omeprazole&#39;s rate of metabolism. Concomitant<br />voriconazole treatment resulted in more than doubling of the Omeprazole exposure. As high<br />doses of Omeprazole have been well-tolerated adjustment of the Omeprazole dose is not<br />generally required. However, dose adjustment should be considered in patients with severe<br />hepatic impairment and if long-term treatment is indicated.<br />Inducers of CYP2C19 and/or CYP3A4<br />Active substances known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St<br />John&#39;s wort) may lead to decreased Omeprazole serum levels by increasing Omeprazole&#39;s rate of<br />metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Results from three prospective epidemiological studies (more than 1000 exposed outcomes)<br />indicate no adverse events of omeprazole on pregnancy or on the health of the foetus/newborn<br />child. Omeprazole can be used during pregnancy.<br />Breast-feeding<br />Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic<br />doses are used.</p><p>Fertility<br />Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate<br />effects with respect to fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omeprazole is not likely to affect the ability to drive or use machines. Adverse reactions such as<br />dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive<br />or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common side effects (1-10% of patients) are headache, abdominal pain, constipation,<br />diarrhoea, flatulence and nausea/vomiting.<br />The following adverse drug reactions have been identified or suspected in the clinical trials<br />programme for Omeprazole and post-marketing. None was found to be dose-related. Adverse<br />reactions listed below are classified according to frequency and System Organ Class (SOC).<br />Frequency categories are defined according to the following convention: Very common ( 1/10),<br />Common ( 1/100 to &lt; 1/10), Uncommon ( 1/1,000 to &lt; 1/100), Rare ( 1/10,000 to &lt; 1/1,000),<br />Very rare (&lt; 1/10,000), Not known (cannot be estimated from the available data).</p><p>SOC/frequency &nbsp; &nbsp; &nbsp;Adverse reaction Blood and lymphatic system disorders</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Leukopenia, thrombocytopenia</p><p>Very rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Agranulocytosis, pancytopenia</p><p>Immune system disorders</p><p>Rare:</p><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic</p><p>reaction/shock</p><p>Metabolism and nutrition disorders</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hyponatraemia</p><p>Very rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hypomagnesaemia</p><p>Psychiatric disorders</p><p>Uncommon: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Insomnia</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Agitation, confusion, depression</p><p>Very rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Aggression, hallucinations</p><p>Nervous system disorders</p><p>Common: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Headache</p><p>Uncommon: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dizziness, paraesthesia, somnolence Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Taste&nbsp;<br />disturbance</p><p><br />Eye disorders</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Blurred vision Ear and labyrinth disorders Uncommon: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br />Vertigo</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bronchospasm</p><p>Gastrointestinal disorders</p><p>Common: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting Rare: &nbsp;<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dry mouth, stomatitis, gastrointestinal candidiasis</p><p>Hepatobiliary disorders</p><p>Uncommon: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Increased liver enzymes</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hepatitis with or without jaundice</p><p>Very rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hepatic failure, encephalopathy in patients with pre-existing liver&nbsp;<br />disease</p><p>Skin and subcutaneous tissue disorders</p><p>Uncommon: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dermatitis, pruritus, rash, urticaria Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Alopecia,&nbsp;<br />photosensitivity</p><p>Very rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal&nbsp;<br />necrolysis (TEN)</p><p>Musculoskeletal and connective tissue disorders</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Arthralgia, myalgia</p><p>Very rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Muscular weakness</p><p>Renal and urinary disorders</p><p>Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Interstitial nephritis</p><p><br />Reproductive system and breast disorders</p><p>Very rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Gynaecomastia</p><p>General disorders and administration site conditions</p><p>Uncommon: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Malaise, peripheral oedema Rare: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Increased sweating</p><p>Paediatric population<br />The safety of Omeprazole has been assessed in a total of 310 children aged 0 to 16 years with<br />acid-related disease. There are limited long term safety data from 46 children who received<br />maintenance therapy of Omeprazole during a clinical study for severe erosive oesophagitis for up<br />to 749 days. The adverse event profile was generally the same as for adults in short- as well as in<br />long-term treatment. There are no long term data regarding the effects of Omeprazole treatment<br />on puberty and growth.</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available on the effects of overdoses of Omeprazole in humans. In<br />the literature, doses of up to 560 mg have been described, and occasional reports have been<br />received when single oral doses have reached up to 2,400 mg Omeprazole (120 times the usual<br />recommended clinical dose). Nausea, vomiting, dizziness, abdominal pain, diarrhoea and<br />headache have been reported. Also apathy, depression and confusion have been described in<br />single cases.<br />The symptoms described have been transient, and no serious outcome has been reported. The<br />rate of elimination was unchanged (first order kinetics) with increased doses. Treatment, if<br />needed, is symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid related disorders, drugs for peptic ulcer and gastrooesophageal<br />reflux disease (GORD), proton pump inhibitors, ATC code: A02BC01<br />Mechanism of action<br />Omeprazole, a racemic mixture of two enantiomers reduces gastric acid secretion through a<br />highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Itis rapidly acting and provides control through reversible inhibition of gastric acid secretion with<br />once daily dosing.<br />Omeprazole is a weak base and is concentrated and converted to the active form in the highly<br />acidic environment of the intracellular canaliculi within the parietal cell, where it inhibits the<br />enzyme H+ K+-ATPase - the acid pump. This effect on the final step of the gastric acid formation<br />process is dose-dependent and provides for highly effective inhibition of both basal acid secretion<br />and stimulated acid secretion, irrespective of stimulus.<br />Pharmacodynamic effects<br />All pharmacodynamic effects observed can be explained by the effect of Omeprazole on acid<br />secretion.<br />Effect on gastric acid secretion<br />Oral dosing with Omeprazole once daily provides for rapid and effective inhibition of daytime and<br />night-time gastric acid secretion with maximum effect being achieved within 4 days of treatment.<br />With Omeprazole 20 mg, a mean decrease of at least 80% in 24-hour intragastric acidity is then<br />maintained in duodenal ulcer patients, with the mean decrease in peak acid output after<br />pentagastrin stimulation being about 70% 24 hours after dosing.<br />Oral dosing with Omeprazole 20 mg maintains an intragastric pH of 3 for a mean time of 17<br />hours of the 24-hour period in duodenal ulcer patients.<br />As a consequence of reduced acid secretion and intragastric acidity, Omeprazole dosedependently<br />reduces/normalizes acid exposure of the oesophagus in patients with gastrooesophageal<br />reflux disease.<br />The inhibition of acid secretion is related to the area under the plasma concentration-time curve<br />(AUC) of Omeprazole and not to the actual plasma concentration at a given time.<br />No tachyphylaxis has been observed during treatment with Omeprazole.<br />Effect on H. pylori<br />H. pylori is associated with peptic ulcer disease, including duodenal and gastric ulcer disease. H.<br />pylori is a major factor in the development of gastritis. H. pylori together with gastric acid are<br />major factors in the development of peptic ulcer disease. H. pylori is a major factor in the<br />development of atrophic gastritis which is associated with an increased risk of developing gastric<br />cancer.<br />Eradication of H. pylori with Omeprazole and antimicrobials is associated with, high rates of&nbsp;healing and long-term remission of peptic ulcers.<br />Dual therapies have been tested and found to be less effective than triple therapies. They could,<br />however, be considered in cases where known hypersensitivity precludes use of any triple<br />combination.<br />Other effects related to acid inhibition<br />During long-term treatment gastric glandular cysts have been reported in a somewhat increased<br />frequency. These changes are a physiological consequence of pronounced inhibition of acid<br />secretion, are benign and appear to be reversible.<br />Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric<br />counts of bacteria normally present in the gastrointestinal tract. Treatment with acid-reducing<br />drugs may lead to slightly increased risk of gastrointestinal infections such<br />as Salmonella and Campylobacter.<br />Chromogranin A (CgA) also increases due to decreased gastric acidity. This CgA modifying effect<br />can not be demonstrated five days after stopping treatment with PPIs.<br />Paediatric use<br />In a non-controlled study in children (1 to 16 years of age) with severe reflux oesophagitis,<br />Omeprazole at doses of 0.7 to 1.4 mg/kg improved oesophagitis level in 90% of the cases and<br />significantly reduced reflux symptoms. In a single-blind study, children aged 0&ndash;24 months with<br />clinically diagnosed gastro-oesophageal reflux disease were treated with 0.5, 1.0 or 1.5 mg<br />Omeprazole/kg. The frequency of vomiting/regurgitation episodes decreased by 50% after 8<br />weeks of treatment irrespective of the dose.<br />Eradication of H. pylori in children<br />A randomised, double blind clinical study (H&eacute;liot study) concluded that Omeprazole in<br />combination with two antibiotics (amoxicillin and clarithromycin), was safe and effective in the<br />treatment of H. pylori infection in children age 4 years old and above with gastritis: H.<br />pylori eradication rate: 74.2% (23/31 patients) with Omeprazole + amoxicillin + clarithromycin<br />versus 9.4% (3/32 patients) with amoxicillin + clarithromycin. However, there was no evidence of<br />any clinical benefit with respect to dyspeptic symptoms. This study does not support any<br />information for children aged less than 4 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Omeprazole and Omeprazole magnesium are acid labile and are therefore administered orally as<br />enteric-coated granules in capsules or tablets. Absorption of Omeprazole is rapid, with peak<br />plasma levels occurring approximately 1-2 hours after dose. Absorption of Omeprazole takes<br />place in the small intestine and is usually completed within 3-6 hours. Concomitant intake of food<br />has no influence on the bioavailability. The systemic availability (bioavailability) from a single oral<br />dose of Omeprazole is approximately 40%. After repeated once-daily administration, the<br />bioavailability increases to about 60%.<br />Distribution<br />The apparent volume of distribution in healthy subjects is approximately 0.3 l/kg body weight.<br />Omeprazole is 97% plasma protein bound.<br />Metabolism<br />Omeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of<br />its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the<br />formation of hydroxyl Omeprazole, the major metabolite in plasma. The remaining part is<br />dependent on another specific isoform, CYP3A4, responsible for the formation of Omeprazole<br />sulphone. As a consequence of high affinity of Omeprazole to CYP2C19, there is a potential for<br />competitive inhibition and metabolic drug-drug interactions with other substrates for CYP2C19.<br />However, due to low affinity to CYP3A4, Omeprazole has no potential to inhibit the metabolism of<br />other CYP3A4 substrates. In addition, Omeprazole lacks an inhibitory effect on the main CYP<br />enzymes.<br />Approximately 3% of the Caucasian population and 15-20% of Asian populations lack a functional<br />CYP2C19 enzyme and are called poor metabolisers. In such individuals the metabolism of<br />Omeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of<br />20 mg Omeprazole, the mean AUC was 5 to 10 times higher in poor metabolisers than in<br />subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma<br />concentrations were also higher, by 3 to 5 times. These findings have no implications for the<br />posology of Omeprazole.<br />Excretion<br />The plasma elimination half-life of Omeprazole is usually shorter than one hour both after single<br />and repeated oral once-daily dosing. Omeprazole is completely eliminated from plasma between<br />doses with no tendency for accumulation during once-daily administration. Almost 80% of an oral<br />dose of Omeprazole is excreted as metabolites in the urine, the remainder in the faeces, primarily&nbsp;originating from bile secretion.<br />The AUC of Omeprazole increases with repeated administration. This increase is dosedependent<br />and results in a non-linear dose-AUC relationship after repeated administration. This<br />time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance<br />probably caused by an inhibition of the CYP2C19 enzyme by Omeprazole and/or its metabolites<br />(e.g. the sulphone).<br />No metabolite has been found to have any effect on gastric acid secretion.<br />Special populations<br />Impaired hepatic function<br />The metabolism of Omeprazole in patients with liver dysfunction is impaired, resulting in an<br />increased AUC. Omeprazole has not shown any tendency to accumulate with once daily dosing.<br />Impaired renal function<br />The pharmacokinetics of Omeprazole, including systemic bioavailability and elimination rate, are<br />unchanged in patients with reduced renal function.<br />Elderly<br />The metabolism rate of Omeprazole is somewhat reduced in elderly subjects (75-79 years of<br />age).<br />Paediatric patients<br />During treatment with the recommended doses to children from the age of 1 year, similar plasma<br />concentrations were obtained as compared to adults. In children younger than 6 months,<br />clearance of Omeprazole is low due to low capacity to metabolise Omeprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats<br />treated with Omeprazole. These changes are the result of sustained hypergastrinaemia<br />secondary to acid inhibition. Similar findings have been made after treatment with H2-receptor<br />antagonists, proton pump inhibitors and after partial fundectomy. Thus, these changes are not<br />from a direct effect of any individual active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sugar spheres<br />Hypromellose<br />Talc<br />Sodium Hydroxide Pellets<br />Methacrylic acid ethyl acrylate<br />Macrogol (Lutrol E400)<br />Titanium Dioxide<br />Purified Water<br />Empty Hard Gelatin Capsule</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.Protect from light</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/Alu blister in packs of 7, 14 and 28<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.
Fax +96626081222
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>